Metastin is not involved in metastatic potential of non-small cell lung cancer

Metastin, the product of the KISS-1 gene, seems to represent a strong suppressant of metastasis for some types of cancer. The aim of this study is to explore whether circulating levels of metastin could be used as a marker for the metastatic potential of non-small cell lung cancer (NSCLC) as well as...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2011-06, Vol.28 (2), p.559-564
Main Authors: Karapanagiotou, Eleni M., Dilana, Kalliopi D., Gkiozos, Ioannis, Gratsias, Ioannis, Tsimpoukis, Sotirios, Polyzos, Aris, Syrigos, Kostas N.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Biomarkers, Tumor - blood
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - pathology
Enzyme-Linked Immunosorbent Assay
Female
Hematology
Humans
Internal Medicine
Kisspeptins
Leptin - blood
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Invasiveness - pathology
Neoplasm Staging
Oncology
Original Paper
Pathology
Tumor Suppressor Proteins - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastin, the product of the KISS-1 gene, seems to represent a strong suppressant of metastasis for some types of cancer. The aim of this study is to explore whether circulating levels of metastin could be used as a marker for the metastatic potential of non-small cell lung cancer (NSCLC) as well as a diagnostic marker in NSCLC patients. The possible correlation between metastin and leptin circulating levels was also evaluated. Fasting serum levels of metastin and leptin were determined in 96 NSCLC patients at diagnosis (76 with metastatic disease and 21 with locally advanced disease) and 49 healthy volunteers using commercial available ELISA. Serum metastin levels presented no differences between NSCLC patients and healthy volunteers (1.18 ± 0.98 vs. 1.17 ± 0.39 ng/ml, P  = 0.979) as well as between patients with metastatic and locally advanced disease (1.17 ± 1.05 vs. 1.21 ± 0.64 ng/ml, P  = 0.872). There was no statistically significant correlation between circulating metastin and leptin levels in NSCLC patients and patients with locally advanced and metastatic disease. This study shows a lack of direct involvement of metastin in the diagnosis and metastatic potential of NSCLC.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-010-9466-7